^
Association details:
| Biomarker: | HR overexpression |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | tamoxifen (Estrogen receptor antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
High-dose tamoxifen in high-hormone-receptor-expressing advanced breast cancer patients: a phase II pilot study
Published date:
02/26/2021
Excerpt:
...study aimed to explore the efficacy of high-dose tamoxifen (TAM) treatment in patients with advanced breast cancer with highly expressed HR....The median PFS was 6 months [95% confidence interval (CI) 4.9-7.1] and the median OS was 15.6 months (95% CI 8.3-22.9)....A high-dose of TAM is effective...
DOI:
10.1177/1758835921993436
Trial ID:
